HK1106534A1 - Proteasome inhibitors and methods of using the same - Google Patents

Proteasome inhibitors and methods of using the same

Info

Publication number
HK1106534A1
HK1106534A1 HK07112239.9A HK07112239A HK1106534A1 HK 1106534 A1 HK1106534 A1 HK 1106534A1 HK 07112239 A HK07112239 A HK 07112239A HK 1106534 A1 HK1106534 A1 HK 1106534A1
Authority
HK
Hong Kong
Prior art keywords
methods
same
proteasome inhibitors
compositions
proteasome activity
Prior art date
Application number
HK07112239.9A
Other languages
English (en)
Inventor
Ambrogio Oliva
Raffaella Bernardnini
Arasmo Germano D
Paolo G Cassara
Alberto Bernareggi
Ernesto Menta
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of HK1106534A1 publication Critical patent/HK1106534A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
HK07112239.9A 2005-02-11 2007-11-09 Proteasome inhibitors and methods of using the same HK1106534A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65237005P 2005-02-11 2005-02-11
US11/351,193 US7468383B2 (en) 2005-02-11 2006-02-09 Proteasome inhibitors and methods of using the same
PCT/US2006/004664 WO2006086600A1 (en) 2005-02-11 2006-02-10 Proteasome inhibitors and methods of using the same

Publications (1)

Publication Number Publication Date
HK1106534A1 true HK1106534A1 (en) 2008-03-14

Family

ID=36579482

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07112239.9A HK1106534A1 (en) 2005-02-11 2007-11-09 Proteasome inhibitors and methods of using the same

Country Status (20)

Country Link
US (2) US7468383B2 (de)
EP (1) EP1846424B1 (de)
JP (1) JP2008530108A (de)
AT (1) ATE456571T1 (de)
AU (1) AU2006213814B2 (de)
CA (1) CA2597273C (de)
CY (1) CY1109985T1 (de)
DE (1) DE602006012013D1 (de)
DK (1) DK1846424T3 (de)
ES (1) ES2339698T3 (de)
HK (1) HK1106534A1 (de)
IL (1) IL184678A (de)
MX (1) MX2007009664A (de)
MY (1) MY147921A (de)
NZ (1) NZ560607A (de)
PL (1) PL1846424T3 (de)
PT (1) PT1846424E (de)
SI (1) SI1846424T1 (de)
TW (1) TWI367886B (de)
WO (1) WO2006086600A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090286791A1 (en) * 2001-11-27 2009-11-19 Takeda Pharmaceutical Company Limited Amide Compounds
WO2007011760A2 (en) * 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
KR101274417B1 (ko) 2005-11-09 2013-06-17 프로테올릭스, 인코퍼레이티드 효소 저해를 위한 화합물
PT2041158E (pt) 2006-06-19 2013-07-17 Onyx Therapeutics Inc Péptido epoxicetonas para inibição de proteassoma
CN105837608B (zh) * 2007-08-06 2018-06-08 米伦纽姆医药公司 蛋白酶体抑制剂及其组合物和用途
WO2009026579A1 (en) * 2007-08-23 2009-02-26 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
HUE029665T2 (en) 2007-10-04 2017-03-28 Onyx Therapeutics Inc Synthesis of crystalline peptide epoxy ketone protease inhibitors and amino acid keto epoxides \ t
EP2212334B1 (de) * 2007-10-16 2012-08-15 Millennium Pharmaceuticals, Inc. Proteasominhibitoren
EP2088205A1 (de) 2008-02-11 2009-08-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) PSMB10: Diagnosemarker und therapeutisches Target für chronische Abstoßung
US20090325903A1 (en) 2008-06-17 2009-12-31 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
CN102238950B (zh) * 2008-08-04 2014-05-07 Chdi基金会股份有限公司 某些犬尿氨酸-3-单加氧酶抑制剂、药物组合物以及使用方法
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
EA035100B1 (ru) 2008-10-21 2020-04-28 Оникс Терапьютикс, Инк. Комбинированная терапия с применением пептид эпоксикетонов
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
EP2238973A1 (de) 2009-04-07 2010-10-13 Cephalon France Lyophilisierte Präparate von Proteasominhibitoren
EP2498793B1 (de) 2009-11-13 2019-07-10 Onyx Therapeutics, Inc. Oprozomib zur verwendung in der metastasensuppression
WO2011087822A1 (en) 2009-12-22 2011-07-21 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
MX2012008346A (es) 2010-01-25 2012-11-12 Chdi Foundation Inc Determinados inhibidores de cinurenina-3-monooxigenasa, composiciones farmceuticas y metodos de uso de los mismos.
BR112012022060A2 (pt) 2010-03-01 2018-05-08 Onyx Therapeutics Inc composto para a inibição de imunoproteassoma
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
US8884009B2 (en) 2010-10-14 2014-11-11 Synthon Bv Process for making bortezomib and intermediates for the process
SI2750677T1 (sl) 2011-08-30 2017-10-30 Chdi Foundation, Inc. Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe
US9428464B2 (en) 2011-08-30 2016-08-30 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
TW201414751A (zh) 2012-07-09 2014-04-16 歐尼克斯治療公司 肽環氧酮蛋白酶抑制劑之前驅藥物
WO2014072985A1 (en) * 2012-11-06 2014-05-15 Natco Pharma Limited Novel boronic acid derivatives as anti cancer agents
US9493439B1 (en) 2014-04-07 2016-11-15 University Of Kentucky Research Foundation Proteasome inhibitors
LT3391941T (lt) * 2014-04-08 2023-11-10 Abliva Ab Nauji pro ląstelę prasiskverbiantys sukcinato junginiai
UY36132A (es) 2014-05-20 2015-11-30 Millennium Pharm Inc Métodos para terapia de cáncer
US10258621B2 (en) 2014-07-17 2019-04-16 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
CN113061144A (zh) * 2017-02-28 2021-07-02 正大天晴药业集团股份有限公司 氮杂环丁烷衍生物
GB201808149D0 (en) 2018-05-18 2018-07-11 Univ Court Univ Of Glasgow Protected amino acids
JP7434273B2 (ja) * 2018-08-02 2024-02-20 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド アゼチジン誘導体のボレート

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3301354A1 (de) 1983-01-18 1984-07-19 Matth. Hohner Ag, 7218 Trossingen Elektronisches musikinstrument
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4537773A (en) 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
AU3418389A (en) 1988-03-28 1989-10-16 Regents Of The University Of California, The Nerve growth factor peptides
US5023236A (en) 1988-04-07 1991-06-11 Corvas, Inc. Factor VII/VIIA active site inhibitors
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US4963655A (en) 1988-05-27 1990-10-16 Mayo Foundation For Medical Education And Research Boron analogs of amino acid/peptide protease inhibitors
US5159060A (en) 1988-05-27 1992-10-27 Mayo Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
DE3827340A1 (de) 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
EP0732399A3 (de) 1990-03-05 1997-03-12 Cephalon Inc Chymotrypsinartige Proteasen und ihre Inhibitoren
ATE149563T1 (de) 1992-08-14 1997-03-15 Procter & Gamble Alpha-aminoborsäurehaltige flüssige waschmittel
WO1994017816A1 (en) 1993-02-10 1994-08-18 The President And Fellows Of Harvard College Role of atp-ubiquitin-dependent proteolysis in mhc-1 restricted antigen presentation and inhibitors thereof
IL109319A0 (en) 1993-04-27 1994-07-31 Du Pont Merck Pharma Amidino and guanidino substituted boronic acid compounds
US5658885A (en) 1993-04-27 1997-08-19 The Dupont Merck Pharmaceutical Company Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
US5672582A (en) 1993-04-30 1997-09-30 Merck & Co., Inc. Thrombin inhibitors
AU670381B2 (en) 1993-04-30 1996-07-11 Merck & Co., Inc. Thrombin inhibitors
FR2707085B1 (fr) 1993-06-30 1995-08-18 Adir Nouveaux dérivés d'alpha amino acides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
CA2171882C (en) 1993-10-01 2001-12-04 Barbara Cordell Inhibitors of .beta.-amyloid protein production
IL111175A0 (en) 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
GB9401483D0 (en) 1994-01-26 1994-03-23 Sandoz Ltd Organic compounds
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5550262A (en) 1994-11-14 1996-08-27 Cephalon, Inc. Multicatalytic protease inhibitors
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
US5834487A (en) 1996-09-24 1998-11-10 Cv Therapeutics Inhibition of 26S and 20S proteasome by indanones
ATE212037T1 (de) 1996-10-18 2002-02-15 Vertex Pharma Inhibitoren von serinproteasen, insbesondere von ns3-protease des hepatitis-c-virus
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
US6096778A (en) 1997-10-07 2000-08-01 Cephalon, Inc. α-ketoamide multicatalytic protease inhibitors
WO1999030707A1 (en) 1997-12-16 1999-06-24 Cephalon Inc. Multicatalytic protease inhibitors for use as anti-tumor agents
US6075150A (en) 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
EP0995757A3 (de) 1998-08-26 2002-05-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bivalente Proteasom Inhibitore
BR9914648A (pt) 1998-10-20 2001-11-27 Millennium Pharm Inc Processo para monitorar ação medicamentosa deinibidor de proteasoma
EP1053750A1 (de) 1999-04-22 2000-11-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Gebrauch von Proteasom-Inhibitor zur Induktion von programmiertem Zelltod (Apoptose)
BR0010134A (pt) 1999-04-27 2002-01-15 Novartis Ag Uso de derivados de ácido 2,4-diamino-3-hidroxicarboxìlico como inibidores de proteassoma
SE9901573D0 (sv) 1999-05-03 1999-05-03 Astra Ab New compounds
AU5788800A (en) 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
US7122627B2 (en) 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
AU7832000A (en) 1999-09-23 2001-04-24 Washington University Compounds directed against pilus biogenesis and activity in pathogenic bacteria;methods and compositions for synthesis thereof
EP1221962A2 (de) 1999-10-20 2002-07-17 Osteoscreen, Inc. Hemmstoffe der proteasom aktivität zur stimulierung von knochen- und haarwachstum
PL365695A1 (en) 2000-07-21 2005-01-10 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
DE50110956D1 (de) 2000-10-12 2006-10-19 Viromics Gmbh Proteasome inhibitoren zur behandlung von hepatitis-virus infektionen
WO2002059131A1 (en) 2001-01-25 2002-08-01 Millennium Pharmaceuticals, Inc. Formulation of boronic acid compounds
KR20040002905A (ko) 2001-04-09 2004-01-07 알란 크리스챤 쇼우 세포내 세균으로부터 단백질을 동정하는 방법
WO2002094857A1 (en) 2001-05-23 2002-11-28 The Curators Of The University Of Missouri Inverse solid phase synthesis of peptides
BR0210112A (pt) 2001-05-30 2004-06-08 Novartis Ag Derivados do ácido 2-{[n-(2-amino-3-(heteroarila ou arila)propionil)-aminoacil]-amino}-alquilborÈnico
KR100399359B1 (ko) * 2001-07-07 2003-09-26 삼성전자주식회사 전하 펌프 회로
AU2002324734A1 (en) 2001-08-16 2003-03-03 Levente Fabry-Asztalos Borinic acid protease inhibitors
JPWO2003033507A1 (ja) 2001-10-12 2005-02-03 杏林製薬株式会社 ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬
US7524883B2 (en) 2002-01-08 2009-04-28 Eisai R&D Management Co., Ltd. Eponemycin and epoxomicin analogs and uses thereof
WO2005016659A1 (ja) 2003-08-13 2005-02-24 Seiko Precision Inc. カードの製造方法及びカード製造装置
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
WO2009020448A1 (en) 2007-08-06 2009-02-12 Millennium Pharmaceuticals, Inc. Proteasome inhibitors

Also Published As

Publication number Publication date
PL1846424T3 (pl) 2010-06-30
PT1846424E (pt) 2010-04-15
MY147921A (en) 2013-02-15
EP1846424B1 (de) 2010-01-27
US7468383B2 (en) 2008-12-23
AU2006213814A1 (en) 2006-08-17
CY1109985T1 (el) 2014-09-10
US20060189806A1 (en) 2006-08-24
MX2007009664A (es) 2007-09-26
WO2006086600A1 (en) 2006-08-17
IL184678A0 (en) 2007-12-03
DE602006012013D1 (de) 2010-03-18
ES2339698T3 (es) 2010-05-24
TWI367886B (en) 2012-07-11
DK1846424T3 (da) 2010-05-17
AU2006213814B2 (en) 2011-10-13
NZ560607A (en) 2009-11-27
IL184678A (en) 2012-05-31
EP1846424A1 (de) 2007-10-24
ATE456571T1 (de) 2010-02-15
CA2597273A1 (en) 2006-08-17
US20090075936A1 (en) 2009-03-19
SI1846424T1 (sl) 2010-05-31
JP2008530108A (ja) 2008-08-07
TW200640936A (en) 2006-12-01
US8283367B2 (en) 2012-10-09
CA2597273C (en) 2013-12-17

Similar Documents

Publication Publication Date Title
TWI367886B (en) Proteasome inhibitors and methods of using the same
HK1091839A1 (en) Proteasome inhibitors and methods of using the same
HK1089153A1 (en) Proteasome inhibitors and methods of using the same
PH12014500053A1 (en) Proteasome inhibitors
MX2019005232A (es) Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
WO2012037155A3 (en) Tyrosine kinase inhibitors
MY166653A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
MY162518A (en) Proteasome inhibitors and methods of using the same
MY180594A (en) Proteasome inhibitors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180210